We were delighted to welcome Baruch Harris, Chief Operating Officer at Pretzel Therapeutics, a company dedicated to translating mitochondrial biology into transformative therapies. Dr. Harris’s journey spans from rigorous scientific roots to strategic leadership — he holds a Ph.D. in Biochemistry and Molecular Biology from UCSF and a degree in Biophysics from Brown University. Before joining Pretzel, he led business development, operations, and fundraising efforts at companies including ROME Therapeutics, Yumanity Therapeutics, Metera Pharmaceuticals, and Enlight Biosciences. In our conversation today, we’ll explore how Pretzel is tackling mitochondrial dysfunction as a therapeutic target, the unique operational challenges of scaling a biotech platform grounded in mitochondrial biology.